Abstract: LT-R192G, a mutant of the thermolabile enterotoxin of E. coli, is a potent adjuvant of immunization. Immune responses are generally analyzed at the end of protocols including at least 2 administrations, but rarely after a prime. To investigate this point, we compared B and T cell responses in mice after one and two intrarectal immunizations with 2/6 rotavirus-like particles (2/6-VLP) and LT-R192G. After a boost, we found, an unexpected lower B cell expansion measured by flow cytometry, despite a secondary antibody response. We then analyzed CD4 
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Introduction
Because systemic immunization is not optimal to induce local immune effectors and requires multiple injections, mucosal immunization is an important goal of vaccine development to protect against pathogens that use mucosa as portals of entry. However, several factors such as antigen degradation in the digestive tract, compartmentalization of the responses at the mucosa of antigen delivery as well as mucosal tolerance make mucosal vaccination with non replicating antigens complex. To generate strong mucosal immune responses, mucosal adjuvants have been proposed. The cholera toxin, CT, and the thermolabile enterotoxin of Escherichia coli, LT, which are well known diarrheagenic toxins produced by V. cholerae and enterotoxinogen E. coli, respectively, are potent mucosal adjuvants for abrogating mucosal tolerance and inducing strong B and T cell immune responses against coadministered antigens. To overcome the enterotoxicity and use them as adjuvant in humans, non toxic mutants of the A subunit have been developed, among them, the protease site mutant of LT, LT-R192G. This mutant retains adjuvant properties in experimental models [1] [2] [3] [4] and has been tested in clinical trials [5] [6] [7] . However, although many studies have reported about the effects of the whole toxins or their mutants on different innate or adaptive immune cells that could explain the adjuvant effect (reviewed in [1] [2] [3] [4] 8, 9] ), the precise mechanism of action of these adjuvants has not been completely elucidated. Of note, the comparison of their different effects on immune responses after a prime and a boost, using the same route and the same immunogen, has not been documented. This comparison may bring relevant cognitive information and, in addition, it may be useful to optimize protocols of immunization.
To better understand early events induced after mucosal priming with a non-replicating antigen, we previously traced rotavirus (RV)-specific B cells by flow cytometry (FCM), after a single intranasal (IN) or intrarectal (IR) administration of RV virus-like particles (2/6-VLP) in mice, in the presence of LT-R192G [10, 11] . 2/6-VLP coadministered intranasally or intrarectally with LT-R192G, in protocols including at least 2 immunizations, have been shown to induce strong T and B cell responses as well as protection against experimental infection [12, 13] . With both routes, we have shown, after a prime, high expansion of specific B cells in different lymphoid tissues, which depend on the route of immunization. A substantial proportion of these cells expressed CD5 and was considered B-1a cells. Unexpectedly, we found that a second IN immunization in the same conditions did not increase the frequency of specific B cells on day 7 following the second immunization, whereas a secondary systemic and mucosal antibody response was observed [11] . As LT-R192G is a potent mucosal adjuvant, this result was therefore difficult to explain. We hypothesized that the massive B cell expansion observed when the adjuvant was used for immunization was probably regulated during the second contact. Such modulation may be important to avoid potential deleterious autoreactivity of CD5 + expressing B-1a cells, as well as T cell-mediated inflammation. Regulatory T lymphocytes (Tregs) are important in suppressing the activation, proliferation and differentiation of T and B cells, and thus control immune responses [14, 15] [17] . In mice, Foxp3 does not make it possible to distinguish between nTregs and iTregs but is considered a useful marker to distinguish between CD4 + T cells with a presumed regulatory-suppressive function and other CD4 + T cells [18] .
In this work, to investigate more in details the effects of LT-R192G after a prime and a boost, we first compared the primary and secondary specific B cell response induced by IR immunization with 2/6-VLP in the presence or in the absence of LT-R192G. Then, we analyzed specific CD25 + CD4 + T cells, both Foxp3 + and Foxp3 − , from different lymphoid tissues, in in vitro response to 2/6-VLP, LT-R192G or both. Quantitative analysis reflecting activation and/or proliferative responsiveness was performed using cell frequency, CD25 and/or Foxp3 mean fluorescence intensity of both subsets, as well as IL-2 production [19] .
Materials and Methods

Mice
Pathogen-free, adult, female BALB/c mice (6-8 weeks of age) were obtained from Iffa-Credo (L'Arbresle, France) or from our in-house facilities. Study protocols were approved by the local institutional animal care committee. No mouse had evidence of previous RV infection, as determined by serum antibody titres.
VLP Preparation and Adjuvant
Two different VLP, containing RV VP2 and VP6 (2/6-VLP) used for immunization or GFP-Δ92VP2 and VP6 used for flow cytometry, were produced in the baculovirus system as described previously [20] . Briefly, Sf9 insect cells were coinfected with two recombinant baculoviruses expressing the protein VP6 of the bovine RF strain and an authentic or a modified GFP-VP2 at a multiplicity of infection higher than 5PFU/cell. VLP were collected 5-7 days post infection and purified by density gradient centrifugation in CsCl.
LT-R192G, a LT mutant, the thermolabile enterotoxin of Escherichia coli, was used as the adjuvant. LT-R192G is a mutant of LT containing a single amino acid substitution that alters the site of proteolytic cleavage within the region joining A1 and A2. This mutation is associated with the reduced ability to induce an accumulation of cAMP in cultured cells as well as reduced enterotoxicity in experimental animals and humans when compared to native LT [2] .
Immunization and Sample Collection
The mice were intrarectally immunized on day 0 with either NaCl, 10 µg LT-R192G alone, 10 µg 2/6-VLP alone or mixed with 10 µg LT-R192G. Prior to immunization, the mice were anesthetized by intraperitoneal administration of a mixture of ketamine (80 mg/kg) and xylazine (16 mg/kg). An additional group of mice was given two doses of 10 µg 2/6-VLP with 10 µg LT-R192G, or 2/6-VLP or LT-R192G alone on day 0 and on day 14. The mice were killed at different time points post-immunization (2, 4, 7 or 14 days) and the different lymphoid tissues, rectal follicles (RF), lumbar lymph nodes (LLN), mesenteric lymph nodes (MLN), Peyer's patches (PP) and spleen were removed. Serum and faecal samples were collected and stored at −20 °C.
Measurement of Rotavirus-Specific Antibodies in Serum and Fecal Samples
Antibody titres in serum and faecal samples were determined by ELISA. Microtitre plates were coated overnight at 4 °C with 100 ng of 2/6-VLP in 100 µL of 0.1 M carbonate/bicarbonate buffer, pH 9.6. The wells were blocked with PBS containing 5% non-fat dry milk for 45 min at 37 °C. Faecal samples were made 10% (wt/vol) by suspension in PBS, pH 7.4. Serial twofold dilutions in PBS-5% non-fat dry milk of serum (starting at 1/100) or faecal extracts (starting at 1/40) were added to the wells and incubated for 40 min at 37 °C. After three washes with PBS-0.05% Tween 20, the plates were incubated for 30 min at room temperature with 1/5000 dilution of biotin-labelled goat anti-mouse IgA, IgG or IgM (Cell Lab, Beckman Coulter). The plates were washed, and 1/4000 of peroxidase-labeled avidin (Cell Lab, Beckman Coulter) was added for 30 min at room temperature. The colour reaction was developed with TMB-Peroxidase Substrate Kit (AbCys.S.A), stopped with 100 µL of H 2 SO 4 0.4N and A 450 was determined. A sample was considered positive if the optical density of the sample well was >0.1 plus the mean of the OD values of the negative control wells. Titres were defined by the inverse of the highest serum dilution giving a positive signal. Negative serum and fecal samples (titre < 100 and <40, respectively) were arbitrarily assigned titres of 50 and 20 (half of 100 and 40), respectively, for statistical calculations [21] .
Preparation of Cells from RF, LLN, MLN, PP and Spleen
Single-cell suspensions were prepared by mechanical dissociation, filtered on 40-µm-pore nylon meshes and washed with incomplete medium (RPMI-1640 supplemented with 0.3% glucose, 100 U penicillin per mL, and 100 µg streptomycin per mL). The cells were counted, labelled and analyzed immediately by FCM or resuspended (4 × 10 6 /mL) in complete medium (incomplete medium plus 10% heat-inactived FCS, 2 mM L-glutamine, 1 mM sodium pyruvate) for in vitro restimulation.
In Vitro Restimulation
Cells from either immunized or non-immunized mice (4 × 10 5 cells/well) were cultured in 96-well plates in the presence of different doses of 2/6-VLP, LT-R192G, 2/6-VLP and LT-R192G or RPMI medium only. The T-cell mitogen concanavalin A (5 µg/mL) was used as the positive control. The cells were incubated at 37 °C with 5% CO 2 and harvested on day 2 and day 4 after restimulation for flow cytometry analysis, and the culture supernatants were frozen at −40 °C until IL-2 assay.
FCM Assays
Rotavirus Specific B Cell Quantification
To detect RV-specific B cells, we used an FCM assay as previously described [10] . Cells from different lymphoid tissues were washed once with PBS 1% BSA 0.1% sodium azide buffer. Pellets containing 2 × 10 6 cells were incubated with a mixture of PE Cy-chrome-labelled anti-B220 (Clone [10] . To delineate RV-specific cell populations and to control for the specificity of the staining, the cells were stained, omitting GFP-VLP, and the quadrant position was fitted eventually, after comparison with identical B cell subsets from non-immunized mice. Absolute numbers of RV-specific B cells were obtained by the quantification of RV-specific B cells among total cells that expressed B220 (B220 high plus B220 low ). In order to compare samples, the number of RV-specific B cells was referred to 10 5 total B220 + cells [11] . 
IL-2 Assay
The IL-2 level in culture supernatants was determined by ELISA, using the AbC601MST Mouse IL-2 Module Set kit (AbCys.S.A). Briefly, microtitre plates were coated with 100 µL of anti-IL-2 monoclonal antibody and incubated overnight at 4 °C. The wells were blocked with PBS containing 0.5% BSA and 0.05% Tween 20 at 4 °C overnight. After two washes with PBS containing 0.05% Tween 20, 50 µL of supernatants were added and incubated with the biotinylated anti-IL-2 monoclonal antibody for 2h. The plates were washed, peroxidase-labeled streptavidine was added and the plates were incubated for 1h. The colour reaction was developed with TMB-Peroxidase Substrate Kit (AbCys.S.A), stopped with 100 µL of H 2 SO 4 0.4 N and A 450 was determined.
Statistics
For B cell analysis, results were expressed as means with SEM. Statistical analysis was performed using SigmaStat software. Pairwise comparisons between non-immunized and immunized mice were made using the Mann-Whitney non-parametric U-test. P-values less than 0.05 were considered statistically significant.
For T cell analysis, comparison of cell frequency, CD25 and Foxp3 MFI between stimulated and non stimulated wells was done by using the Wilcoxon paired non-parametric signed-rank test. P-values less than 0.05 were considered statistically significant. In addition, comparisons between non-immunized and immunized mice were made using the Mann-Whitney unpaired non-parametric U-test.
Results
Primary and Secondary Specific B Cell Responses Induced by IR Immunization with 2/6-VLP with or without LT-R192G
3.1.1. The Secondary Response Induced by IR Immunization with 2/6-VLP and LT-R192G Showed a Serum and Fecal Antibody Response but a Lower RV-Specific B Cell Expansion Mice were immunized once or twice with 2/6-VLP or NaCl in the presence of adjuvant, and the RV-specific B cell response analyzed as described previously [10] . On day 7 after the second dose, a secondary antibody response was observed in serum (IgA 3.7 vs. 1.7 log and IgG 5 vs. 1.7 log, for the secondary and primary response, respectively) and in feces (IgA 3.4 vs. 1.4 log) (Figure 1 ), as already shown with the IN route of immunization [11] . suggesting the efficacy of this molecule. The maximum was observed at doses of 0.5 and 1 µg/mL (about 70%)(data not shown).
In vitro culture with both 2/6-VLP and LT-R192G. When cells were cultured with both antigen and adjuvant, the results were similar to those observed with LT-R192G ( Figure 3D ). The results were similar to those observed with non-immunized mice ( Figure 3B , data not shown). Dose-effect. The maximum effect on CD25 expression was observed at the same doses as for control mice and the increase in Foxp3 expression was observed at the dose of 5 µg/mL on day 2 and at all the doses on day 4 (data not shown).
Analysis of CD4
All together, these results show major effects of LT-R192G on CD4
which are different between non-immunized and mice immunized in the presence of adjuvant (i.e., first and second contact with LT-R192G).
In vitro culture with both 2/6-VLP and LT-R192G. Compared to wells cultured in the presence of 2/6-VLP alone, we observed a decrease in CD4 
Discussion
In this work, we have shown an unexpected lower RV-specific B cell expansion measured by flow cytometry after two IR immunizations with RV-VLP and LT-R192G, compared to a single immunization, despite a trend towards a higher response on day 4 for the B220 int subset, consistent with a conventional secondary antibody response. Of note, the primary and secondary responses were not different in mice immunized in the absence of adjuvant. In these conditions, a great variability was observed between mice after one or two immunizations, without any correlation between the magnitude of the B cell response analyzed by flow cytometry and the antibody response. Analysis of antibody secreting cells by Elispot in the lamina propria and the bone marrow may have probably shown a better correlation with the antibody response. Nevertheless, these results which, confirm previous results obtained via the intranasal route, suggest that most B cells analyzed by FCM probably do not differentiate into antibody secreting cells and could have another role in the early response. Firstly, they may be important in antigen presentation and thus impact on T cell responses. Secondly, a large proportion of the B cells analyzed were B1-a cells expressing CD5, in the primary [10] as well as in the secondary response (data not shown). B1-a cells produce natural polyspecific antibodies which most likely play a role in early protection during experimental challenge. However, natural antibodies are also potentially auto-reactive [22] , especially as high frequencies are induced. Thus, we hypothesized that these cells should be regulated to avoid deleterious autoreactivity.
Immunomodulation is an intrinsic property of the immune system and is partially mediated by T cells. Tregs include different subsets comprising natural and inducible CD4 + Tregs expressing CD25 and Foxp3 that we wanted to investigate first, notably because we hypothesized that nTregs should be involved early to control auto-immune reactivity. Quantitative analysis reflecting activation and/or proliferative responsiveness of CD4 + CD25 + Foxp3 + T cells, presumably Tregs (nTregs or iTregs), was performed using cell frequency, CD25 and Foxp3 mean fluorescence intensity in in vitro culture experiments in the presence of the antigen, the adjuvant or both, as this method is classically used to study T cells [19] . [14] and no IL-2 was produced in these wells. However, the decrease was more important in the presence of LT-R192G and both 2/6-VLP and LT-R192G. Moreover, there were major differences between the antigen and the adjuvant, as 2/6-VLP induced a weak but homogenous decrease in Foxp3 expression leading to a weak decrease in CD4 Of note, T cell activation was observed for all the lymphoid organs and tissues analyzed indicating that T cell migration differs from B cell migration after IR immunization, as previously shown for the IN route. Indeed B cells were not found in PP in both cases or in the spleen with the IR route, whereas T cells were found in these tissues [11, 23] . This result was made possible because our model allowed us to trace both specific B and T cells. The migration of primary and memory RV specific CD8+ T cells in several non lymphoid and lymphoid tissues has also been reported previously [24] . cell frequency did not decrease anymore. Similar results were observed for mice immunized with LT-R192G alone (data not shown). Thus the major decrease in this subpopulation, observed after a first contact, may be attributed to specific apoptosis of nTregs induced by LT-R192G, whereas in vivo induced Tregs, specific either for LT-R192G or for 2/6-VLP, may be less susceptible to apoptosis. Moreover, Tregs specific for LT-R192G can be recalled in vitro as shown by the increase in Foxp3 expression and probable proliferation. All together, these results suggest that LT-R192G induces specific Tregs during the prime that can be recalled in vitro and also promotes the induction of antigen specific Tregs.
As observed during a first contact with LT-R192G, we found a decrease in CD25 expression during a second contact. CD25 is the α chain of the IL-2 receptor and is necessary to form, with the β and γ chains, the trimeric receptor, necessary for high affinity binding of IL-2. A decrease in CD25 expression may result in impairment in Treg maintenance and/or activation and/or function. However, it has been reported recently [25] − T cells, the resulting weak IL-2 production reducing the activation of 2/6-VLP specific iTregs. Of note, the effect of LT-R192G on CD25 expression is consistent with previous results which showed a decrease in CD25 expression on activated CD4 + T cells by anti-CD3 or phytohemagglutinin [26, 27] , though in the previous experiments, CT and a mitogen or anti-CD3 were used. Moreover, we found that LT-R192G also modulates CD4 + T cells, both Foxp3 + and Foxp3 − , activated by conA (data not shown). Thus, LT-R192G which, like LT or CT, is a potent mucosal adjuvant for inducing immune B and T cell responses, is also able to induce specific Tregs and promote iTregs against 2/6-VLP. In accordance with our results, Lavelle et al. have shown that CT induces Tr1 T cells that suppressed IFNγ production after SC immunization [28] . We propose that Tregs induced in our model could modulate not only B cell expansion during the secondary response, but also memory T cell activation to avoid auto-immunity as well as inflammation. Of note, one cannot exclude that CD4 + CD25 + Foxp3 − cells contain regulatory T cells, such as Tr1 which express CD25 after activation [29] .
Induction of CD4 + CD25 + Foxp3 + Tregs has been reported for the B subunit of CT when administered in a conjugated form to OVA, thus resulting in mucosal tolerance [30] . The importance of B cells in the induction of Tregs in this context has been reported. Moreover, it has been reported recently [31] that a subpopulation of B cells expressing CD1d(hi) and CD5 is a unique subset of potent regulatory B cells involved in auto-immunity and inflammatory models, IL-10 being a key component in B-cell-mediated immune regulation [32] . So, the high B cell expansion observed in our model during the primary response, which may have an important role in antigen presentation and in producing natural polyreactive antibodies, critical for protection against infection, could also play a role in limiting the inflammatory mechanisms and autoimmunity that could be induced in the context of a strong response to the presence of adjuvant. B cells may exert a regulatory role either by themselves and/or by inducing Tregs. Although we could not demonstrate a direct effect of LT-R192G in vivo, we argue, on the basis of in vitro experiments, that the first contact in vivo with LT-R192G in a context of low IL-2, may induce countersuppression by decreasing Treg numbers and/or activation, thus allowing naïve B and T cell activation as well as B1-a cell expansion, which would account for the adjuvant effect. Tregs should be also induced by both the antigen and the adjuvant and may control immune responses during the secondary response. Specific B cells may also play a role either as regulatory B cells or by inducing Tregs. Consistent with our hypothesis, we found that immunization during the boost with 2/6-VLP alone (i.e., without adjuvant), did not induce lower Ab responses compared to a boost with LT-R192G (data not shown). These findings ask for the need to use the adjuvant during the boost, the amplitude of the memory antibody response being most likely determined during the prime.
Conclusions
The 
